ZA200708525B - Substituted glycinamides having an antithrombotic and factor xa-inhibiting effect - Google Patents

Substituted glycinamides having an antithrombotic and factor xa-inhibiting effect

Info

Publication number
ZA200708525B
ZA200708525B ZA200708525A ZA200708525A ZA200708525B ZA 200708525 B ZA200708525 B ZA 200708525B ZA 200708525 A ZA200708525 A ZA 200708525A ZA 200708525 A ZA200708525 A ZA 200708525A ZA 200708525 B ZA200708525 B ZA 200708525B
Authority
ZA
South Africa
Prior art keywords
antithrombotic
factor
inhibiting effect
substituted glycinamides
glycinamides
Prior art date
Application number
ZA200708525A
Other languages
English (en)
Inventor
Priepke Henning
Dahmann Georg
Gerlach Kai
Pfau Roland
Wienen Wolfgang
Schuler-Metz Annette
Handschuh Sandra
Nar Herbert
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ZA200708525B publication Critical patent/ZA200708525B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200708525A 2005-06-30 2007-10-05 Substituted glycinamides having an antithrombotic and factor xa-inhibiting effect ZA200708525B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05014270 2005-06-30

Publications (1)

Publication Number Publication Date
ZA200708525B true ZA200708525B (en) 2009-08-26

Family

ID=35907001

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200708525A ZA200708525B (en) 2005-06-30 2007-10-05 Substituted glycinamides having an antithrombotic and factor xa-inhibiting effect

Country Status (33)

Country Link
US (3) US20100216769A1 (he)
EP (1) EP1899330B9 (he)
JP (1) JP4768016B2 (he)
KR (1) KR101321722B1 (he)
CN (1) CN101213195B (he)
AR (1) AR054627A1 (he)
AT (1) ATE489381T1 (he)
AU (1) AU2006265216B2 (he)
BR (1) BRPI0612580A8 (he)
CA (1) CA2613059C (he)
CY (1) CY1111627T1 (he)
DE (1) DE502006008392D1 (he)
DK (1) DK1899330T3 (he)
EA (1) EA015188B1 (he)
EC (1) ECSP078058A (he)
ES (1) ES2357029T3 (he)
HK (1) HK1116190A1 (he)
HR (1) HRP20110044T2 (he)
IL (1) IL188323A (he)
MX (1) MX2007016253A (he)
MY (1) MY145883A (he)
NO (1) NO340670B1 (he)
NZ (1) NZ565440A (he)
PE (1) PE20070171A1 (he)
PL (1) PL1899330T3 (he)
PT (1) PT1899330E (he)
RS (1) RS51572B (he)
SG (1) SG163540A1 (he)
SI (1) SI1899330T1 (he)
TW (1) TWI392495B (he)
UA (1) UA94910C2 (he)
WO (1) WO2007003536A1 (he)
ZA (1) ZA200708525B (he)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2582235A1 (en) 2004-10-04 2006-04-20 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
CA2692440A1 (en) * 2006-07-20 2008-01-24 Cascade Therapeutics Inc. Tetrahydro-5h-pyrido[2,3-d]azepines as 5-ht2c ligands
PE20081834A1 (es) * 2006-12-31 2009-01-16 Boehringer Ingelheim Int Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos
EP1975165A1 (de) 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel
EP2220079A2 (en) * 2007-11-15 2010-08-25 Boehringer Ingelheim International GmbH Substituted amides, manufacturing and use thereof as medicaments
US8288397B2 (en) 2007-12-17 2012-10-16 Janssen Pharmaceutica Nv Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
JP5684719B2 (ja) 2008-12-05 2015-03-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｐｌｋ阻害剤としての５，７−ジヒドロ−６ｈ−ピリミド［５、−４ｄ］［１］ベンゾアゼピン−６−チオン
AU2010216632A1 (en) * 2009-02-17 2011-08-04 Msd K.K. 1,4-benzodiazepin-2-on derivatives
US9708373B2 (en) 2010-03-30 2017-07-18 Icahn School Of Medicine At Mount Sinai Influenza virus vaccine and uses thereof
EA201490659A1 (ru) 2011-09-20 2014-11-28 Маунт Синай Скул Оф Медсин Вакцины против вируса гриппа и их применения
JP2016508133A (ja) 2012-12-18 2016-03-17 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
EP3102200B1 (en) * 2014-02-07 2023-04-05 Exithera Pharmaceuticals Inc. Therapeutic compounds and compositions
CN105622511B (zh) * 2014-11-03 2018-01-23 北京瑞都医药科技有限公司 一种减肥药物及其制备方法
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
PT3818051T (pt) 2018-07-05 2022-10-24 Bayer Ag Tiofenocarboxamidas substituídos e análogos como agentes antibacterianos
CN111196772B (zh) * 2018-11-16 2022-09-30 沈阳化工研究院有限公司 一种芳酰氨基异丁酰衍生物及其应用
TW202135662A (zh) 2019-12-20 2021-10-01 德商拜耳廠股份有限公司 噻吩基㗁唑啉酮及類似物
US11691960B2 (en) 2020-11-06 2023-07-04 Boehringer Ingelheim International Gmbh 2-[thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamide derivatives and the use thereof as medicament

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1192132B1 (en) * 1999-06-14 2005-09-07 Eli Lilly And Company Serine protease inhibitors
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
US7071184B2 (en) 2000-03-21 2006-07-04 Smithkline Beecham Corporation Protease inhibitors
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
EP1401453A4 (en) * 2001-05-17 2005-04-06 Smithkline Beecham Corp PROTEASE INHIBITORS
AR042064A1 (es) 2002-11-19 2005-06-08 Takeda Pharmaceutical Compuestos de amina con actividad inhibidora de la union al receptor de somastotina
JP2004300133A (ja) * 2002-11-19 2004-10-28 Takeda Chem Ind Ltd アミン誘導体
DE10254336A1 (de) * 2002-11-21 2004-06-03 Merck Patent Gmbh Carbonsäureamide
US7250415B2 (en) * 2003-06-04 2007-07-31 Bristol-Myers Squibb Company 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors
KR20070012552A (ko) 2004-05-13 2007-01-25 베링거 인겔하임 인터내셔날 게엠베하 신규한 치환된 티오펜카복스아미드, 이의 제조방법 및약제로서의 이의 용도
EP1748996A1 (de) * 2004-05-13 2007-02-07 Boehringer Ingelheim International GmbH Substituierte thiophencarbonsäureamide, deren herstellung und deren verwendung als arzneimittel
EP1748997A1 (de) 2004-05-13 2007-02-07 Boehringer Ingelheim International Gmbh Substituierte thiophen-2-carbonsäureamide, deren herstellung und deren verwendung als arzneimittel
DE102004047840A1 (de) * 2004-09-29 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Thiophencarbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
PE20081834A1 (es) 2006-12-31 2009-01-16 Boehringer Ingelheim Int Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos

Also Published As

Publication number Publication date
DE502006008392D1 (de) 2011-01-05
AR054627A1 (es) 2007-07-04
TW200738692A (en) 2007-10-16
CN101213195A (zh) 2008-07-02
HK1116190A1 (en) 2008-12-19
KR20080033318A (ko) 2008-04-16
CA2613059C (en) 2013-12-24
US9062034B2 (en) 2015-06-23
NO20075186L (no) 2008-02-14
ECSP078058A (es) 2008-01-23
HRP20110044T1 (en) 2011-02-28
US20150252050A1 (en) 2015-09-10
US9676781B2 (en) 2017-06-13
SI1899330T1 (sl) 2011-03-31
WO2007003536A1 (de) 2007-01-11
BRPI0612580A8 (pt) 2017-12-26
NO340670B1 (no) 2017-05-29
UA94910C2 (ru) 2011-06-25
CA2613059A1 (en) 2007-01-11
EP1899330B9 (de) 2011-11-09
TWI392495B (zh) 2013-04-11
KR101321722B1 (ko) 2013-10-25
PE20070171A1 (es) 2007-03-08
HRP20110044T2 (hr) 2012-02-29
AU2006265216B2 (en) 2011-09-29
PT1899330E (pt) 2011-01-11
CN101213195B (zh) 2012-05-09
MX2007016253A (es) 2008-03-07
DK1899330T3 (da) 2011-02-21
IL188323A0 (en) 2008-04-13
EP1899330B1 (de) 2010-11-24
ES2357029T3 (es) 2011-04-15
NZ565440A (en) 2011-04-29
EA200702620A1 (ru) 2008-06-30
SG163540A1 (en) 2010-08-30
JP2008546741A (ja) 2008-12-25
US20130184256A1 (en) 2013-07-18
JP4768016B2 (ja) 2011-09-07
US20100216769A1 (en) 2010-08-26
PL1899330T3 (pl) 2011-05-31
AU2006265216A1 (en) 2007-01-11
ATE489381T1 (de) 2010-12-15
EP1899330A1 (de) 2008-03-19
RS51572B (en) 2011-08-31
CY1111627T1 (el) 2015-10-07
MY145883A (en) 2012-05-15
IL188323A (he) 2013-08-29
EA015188B1 (ru) 2011-06-30
BRPI0612580A2 (pt) 2010-11-23

Similar Documents

Publication Publication Date Title
ZA200708525B (en) Substituted glycinamides having an antithrombotic and factor xa-inhibiting effect
GB0523969D0 (en) Inductivwe component
DE502005002164D1 (en) Modulares transfersystem für werkstücke
DE502005002050D1 (en) Trainingsstock für sportler
IL189252A0 (en) Dihydroxyanthraquinones and their use
EP1912921A4 (en) COMPOUNDS ON TETRAAZAPORPHYRINBASE AND ITS USES
GB2446908B (en) Structure and connection member for structure
EP1921066A4 (en) PYRIDYLPHENOL COMPOUND AND USE THEREOF
IL191825A0 (en) Fitting structure
GB0520176D0 (en) Use
GB0511190D0 (en) Use
GB0520344D0 (en) Microoganisms
DE112005000793D2 (en) Vibrationsgerät für rammgut mit lagern für rotierende unwuchtmassen
GB0502250D0 (en) Use
GB0526031D0 (en) Use
GB0526032D0 (en) Use
GB0711110D0 (en) Close-coupled fitting
GB0503644D0 (en) Catstep I
GB0524433D0 (en) Contents-relating arrangements
GB0502843D0 (en) Jig-was and jig-will
GB2431102B (en) Vessel-filling arrangements
GB0525328D0 (en) Compounds and their uses
GB0514471D0 (en) Compounds and their uses
GB0515688D0 (en) Compounds and their uses
GB0510263D0 (en) Compounds and their uses